Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
21 juin 2023 09h03 HE
|
Vaccitech plc
Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level,...
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
12 juin 2023 07h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments
12 mai 2023 08h00 HE
|
Vaccitech plc
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
17 avr. 2023 09h00 HE
|
Vaccitech plc
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human...
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
28 mars 2023 08h00 HE
|
Vaccitech plc
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen...
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
24 mars 2023 08h06 HE
|
Vaccitech plc
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development...
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
20 mars 2023 08h00 HE
|
Vaccitech plc
VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs)Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6...
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
30 janv. 2023 08h00 HE
|
Vaccitech plc
Dr. Pelletier joins leadership team to continue the advancement of Vaccitech’s diverse clinical pipeline and partnerships, bringing more than 15 years’ experience in pharmaceuticals and academia in...
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases
21 nov. 2022 10h31 HE
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application...
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
10 nov. 2022 16h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview...